Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
BusinessWire - Wed Jan 06, 1:00AM CST
Regulatory News:
Transgene Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Oct 21, 10:45AM CDT
Regulatory News:
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
BusinessWire - Wed Aug 19, 10:45AM CDT
Regulatory News:
Transgene Reports First Quarter 2015 Financial Results
BusinessWire - Wed Apr 22, 11:00AM CDT
Regulatory News:
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 42.10 (-0.18), NWBO: 0.50 (+0.01), ZIOP: 5.01 (-0.66), PCYC: 261.25 (+1.70), CVM: 0.46 (-0.02), PFE: 36.77 (-0.15), CLDX: 4.70 (+0.22), IMGN: 2.76 (+0.02), BMY: 76.00 (-0.77), RIGL: 2.18 (+0.05), INO: 8.88 (+0.07), KITE: 48.66 (+0.69), LH: 136.19 (-0.13), ABBV: 63.32 (-0.30), PBYI: 32.98 (+0.62)